ChromaDex Corp.: directors' dealings · United States · SEC (Form 4)

About ChromaDex Corp.

ChromaDex Corp. is a United States-based company listed on the NASDAQ, operating at the intersection of consumer health, nutritional ingredients, and science-led biotechnology. Headquartered in Longmont, Colorado, United States, the company has evolved from its earlier roots in analytical reference standards and botanical materials into a more focused business centered on Niagen-related products and the Tru Niagen consumer brand. This strategic shift has made ChromaDex a more visible name in the healthy-aging and NAD+ supplement category. ([standards.chromadex.com](https://standards.chromadex.com/about-us?utm_source=openai)) Today, ChromaDex’s business model is built around several complementary activities. The primary growth engine is its consumer products segment, led by Tru Niagen, a dietary supplement marketed directly to consumers and through distribution channels. The company also generates revenue from ingredient sales, particularly food-grade Niagen, which supports partnerships with third-party brands and manufacturers. Historically, ChromaDex also operated an analytical reference standards and services segment, but in early 2026 it sold substantially all of the assets of that business, indicating a stronger focus on the core Niagen platform and higher-margin consumer and ingredient opportunities. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001386570/000138657026000014/exhibit991-pressreleasexq4.htm?utm_source=openai)) From a competitive standpoint, ChromaDex’s differentiation lies in its intellectual property, scientific positioning, and brand recognition. The company emphasizes its patent portfolio around nicotinamide riboside, and in December 2025 it acquired the core NR patent portfolio from Queen’s University Belfast, strengthening its ownership of foundational composition-of-matter IP. This is strategically important because it supports both consumer wellness claims and the potential future development of pharmaceutical applications. ChromaDex also uses its CERP research collaborations to support publications and reinforce scientific credibility, which is essential in a category where clinical evidence and trust matter. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001386570/000138657026000013/cdxc-20251231.htm?utm_source=openai)) Recent developments have been constructive overall. In its 2025 reporting, ChromaDex highlighted meaningful revenue growth and improved profitability, with Tru Niagen sales and ingredient sales as key contributors. In January 2026, the company announced a partnership with Truemed that allows eligible U.S. customers to use HSA and FSA funds for Tru Niagen purchases on the direct-to-consumer website, a potentially helpful catalyst for conversion and affordability. The company also reported the sale of its analytical standards business in February 2026, a move that should simplify the story and concentrate resources on strategic priorities. A product recall in parts of Asia in late 2025 also illustrated the regulatory and quality-control risks that come with international distribution. ([investors.chromadex.com](https://investors.chromadex.com/news/news-details/2025/ChromaDex-Corporation-Reports-Fourth-Quarter-and-Fiscal-Year-2024-Results/default.aspx?utm_source=openai)) For investors, ChromaDex should be viewed as a science-backed consumer health and ingredient company with a premium positioning in the NAD+ / longevity theme. Its NASDAQ listing in the United States gives it access to U.S. capital markets, while its future performance will likely depend on sustained Tru Niagen adoption, continued IP monetization, and disciplined execution as the company becomes more concentrated around its core Niagen franchise.